Effect of Low-Dose Statins and Apolipoprotein E Genotype on Cerebral Small Vessel Disease in Older Hypertensive Patients: A Subgroup Analysis of a Randomized Clinical Trial

Journal of the American Medical Directors Association
Tiantian JiZhendong Liu

Abstract

To investigate the effect of low-dose statins and apolipoprotein E (APOE) genotypes on cerebral small vessel disease (CSVD) to prevent CSVD in older hypertensive patients. A subgroup analysis of a randomized clinical trial. Shandong area, China. Hypertensive patients aged ≥60 years were recruited from April 2008 to November 2010. Patients were randomly assigned to rosuvastatin (10 mg/day) or placebo groups. APOE genotypes were categorized as ε4 carriers and non-ε4 carriers. White matter hyperintensities (WMH), Fazekas scale, lacunes, and microbleeds were assessed. After an average of intervention period of 61.8 months, WMH volume increased 1.45 ± 0.52 mL. There were 107 new-incident Fazekas scale ≥2, 65 new-incident lacunes, and 63 new-incident microbleeds. The increase in WMH volume was significantly lower in the rosuvastatin group than in the placebo group and was higher in APOE ε4 carriers than in non-ε4 carriers (all adjusted P < .001). The risk of new-incident Fazekas scale ≥2 was higher in the placebo group than in the rosuvastatin group (hazard ratio 2.150, 95% confidence interval 1.443-3.203; P < .001). APOE ε4 carriers were associated with an increased risk of new-incident Fazekas scale ≥2 compared with non-ε4 carriers...Continue Reading

Citations

Sep 27, 2018·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Hua ZhangZhendong Liu
Mar 7, 2020·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·A H KatsanosA Shoamanesh
Mar 24, 2020·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yi CuiZhendong Liu
May 21, 2020·Frontiers in Aging Neuroscience·Akihiro ShindoHidekazu Tomimoto
Nov 12, 2019·Frontiers in Physiology·Muzaimi MustaphaMazira Mohamad Ghazali
Nov 14, 2020·Journal of the Neurological Sciences·Aristeidis H KatsanosUNKNOWN International META-MICROBLEEDS Initiative
Feb 11, 2021·Journal of Neurology, Neurosurgery, and Psychiatry·Laurent PuyCharlotte Cordonnier
May 19, 2021·Stroke; a Journal of Cerebral Circulation·Michelle C JohansenPaul Nyquist
May 11, 2021·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Ruth StephenUNKNOWN FINGER Study Group
Aug 21, 2021·European Stroke Journal·Joanna M WardlawArne G Lindgren
Mar 4, 2020·La Revue de médecine interne·A Garnier-CrussardP Krolak-Salmon
Oct 8, 2020·Cardiology in Review·Bhawneet Chadha, William H Frishman

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.